CSTL Castle Biosciences Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: CSTL

Price (delayed)

$34.88

Market cap

$1.07B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.65

Enterprise value

$1.04B

?
Relative Growth: Rel. Growth: 33
Relative Strength: Rel. Strength: 88
Relative Valuation: Rel. Valuation: 17
Relative Profitability: Rel. Profitability: 31
Highlights
CSTL's revenue is up by 5% from the previous quarter and by 3.2% YoY
The gross profit has grown by 4.3% from the previous quarter
CSTL's EPS has dropped by 110% year-on-year and by 55% since the previous quarter
The net income has dropped by 105% year-on-year and by 51% since the previous quarter
Sector: Healthcare
Industry: Diagnostics & Research
Website: http://castlebiosciences.com
Peers: OPK ORGO

Key stats

What are the main financial stats of CSTL

CSTL stock price

How has the Castle Biosciences stock price performed over time
Intraday
0.09%
1 week
-1.69%
1 month
1.99%
1 year
48.05%
YTD
-10.33%
QTD
46.25%

Financial performance

How have Castle Biosciences's revenue and profit performed over time
Revenue
$357.28M
Gross profit
$276.03M
Operating income
-$32.11M
Net income
-$19.42M
Gross margin
77.3%
Net margin
-5.4%
The net income has dropped by 105% year-on-year and by 51% since the previous quarter
The net margin has shrunk by 100% YoY and by 42% QoQ
The operating income has contracted by 39% YoY but it has grown by 3.5% from the previous quarter
The operating margin has declined by 34% year-on-year but it has grown by 8% since the previous quarter

Price vs fundamentals

How does CSTL's price correlate with its fundamentals

Growth

What is Castle Biosciences's growth rate over time

Valuation

What is Castle Biosciences stock price valuation
CSTL P/E details
P/E
N/A
P/B
2.25
P/S
2.97
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.91
CSTL's EPS has dropped by 110% year-on-year and by 55% since the previous quarter
CSTL's price to book (P/B) is 32% higher than its last 4 quarters average of 1.7 and 25% higher than its 5-year quarterly average of 1.8
The equity is up by 3.2% year-on-year
The P/S is 34% below the 5-year quarterly average of 4.5 but 24% above the last 4 quarters average of 2.4
CSTL's revenue is up by 5% from the previous quarter and by 3.2% YoY

Efficiency

How efficient is Castle Biosciences business performance
The ROE has shrunk by 100% YoY and by 50% QoQ
Castle Biosciences's return on assets has shrunk by 94% YoY and by 52% QoQ
CSTL's return on sales has dropped by 83% year-on-year and by 3.9% since the previous quarter
Castle Biosciences's return on invested capital has shrunk by 63% YoY and by 4% QoQ

Dividends

What is CSTL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CSTL.

Financial health

How did Castle Biosciences financials performed over time
Castle Biosciences's quick ratio has decreased by 13% YoY and by 11% QoQ
CSTL's current ratio is down by 12% year-on-year and by 11% since the previous quarter
The debt is 92% lower than the equity
The equity is up by 3.2% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.